Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532573 | 1.00 | HSD17B10 (0.56) | HSD17B10GAANPSR1MRGPRX4TSHR | |
| SCHEMBL10618516 | 0.86 | HSD17B10 (0.53) | HSD17B10GAANPSR1TSHRALDH1A1 | |
| SCHEMBL2334035 | 0.85 | HSD17B10 (0.51) | HSD17B10GAANPSR1MRGPRX4TSHR | |
| SCHEMBL3234088 | 0.84 | CXCL8 (0.53) | HSD17B10GAANPSR1MRGPRX4TDP1 | |
| SCHEMBL9899219 | 0.84 | GLA (0.46) | HSD17B10MRGPRX4TSHRCXCL8LMNA | |
| SCHEMBL27828872 | 0.83 | POLB (0.54) | MRGPRX4LMNAPOLB | |
| SCHEMBL9979371 | 0.79 | RXRA (0.42) | HSD17B10TSHRCXCL8PDE4BPDE4D | |
| SCHEMBL4600040 | 0.79 | MRGPRX4 (0.40) | GAAMRGPRX4TSHRALDH1A1LMNA | |
| SCHEMBL6343545 | 0.79 | HSD17B10 (0.70) | HSD17B10GAANPSR1TSHRALDH1A1 | |
| SCHEMBL29431167 | 0.79 | HSD17B10 (0.70) | HSD17B10GAANPSR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380682-A | Synthesis method of 2, 3-difluoro-4-methoxyphenylacetic acid | 上海毕得医药科技股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| CN-114380682-A | Synthesis method of 2, 3-difluoro-4-methoxyphenylacetic acid | 上海毕得医药科技股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114380682-A | Synthesis method of 2, 3-difluoro-4-methoxyphenylacetic acid | 上海毕得医药科技股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114380682-A | Synthesis method of 2, 3-difluoro-4-methoxyphenylacetic acid | 上海毕得医药科技股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | disclosed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100120730-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| EP-2109610-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2, 3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | Nycomed GmbH (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008095835-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2, 3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1953159-A1 | 6-Benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds useful as PDE5 inhibitors | Nycomed GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | HSD17B10 2032/4885GAA 1004/4885NPSR1 2391/4885 |
| US-20100120730-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | PDE5A, PDE3A, PDE2A | HSD17B10 1121/4885GAA 1775/4885NPSR1 908/4885 |
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | HSD17B10 233/4885GAA 1954/4885NPSR1 465/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | HSD17B10 362/4885GAA 586/4885NPSR1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.